NEFL and Alzheimer disease: Moreover, increased plasma GFAP was more associated with the clinical incidence of AD (9 to 17 years before diagnosis) than pTau-181 and the NfL (up to 9 years before diagnosis), making this protein the most accurate predictive biomarker for AD from all three [39].